This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lannett Reports Strong Fiscal 2013 First Quarter Financial Results

Conference Call Information and Forward-Looking Statements

Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for the fiscal 2013 first quarter ended September 30, 2012. The conference call will be available to interested parties by dialing 866-813-5647 from the U.S. or Canada, or 847-619-6249 from international locations, passcode 33664467. The conference call will also be available through a live audio Internet broadcast at A playback of the call will be archived and accessible at this site for at least three months.

Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company’s financial status and performance and regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

About Lannett Company, Inc.:

Lannett Company, founded in 1942 and celebrating its 70 th anniversary, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company’s website at

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, expected product approvals, the successful commercialization of products in development, product applications pending at the FDA and recently approved products, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company's judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.
(In thousands, except for share and per share data)
Three months ended
September 30,


Net sales $ 35,294 $ 28,878
Cost of sales 21,164 19,742
Amortization of intangible assets 471 468
Product royalties   33     52  
Gross profit 13,626 8,616
Research and development expenses 3,764 2,426
Selling, general, and administrative expenses   6,171     4,745  
Operating income   3,691     1,445  
Other income (expense):
Foreign currency gain 3 5
Gain on sale of assets 70 7
Realized loss on investments (36 ) (173 )
Unrealized gain (loss) on investments 270 (826 )
Litigation settlement 1,250 -
Interest and dividend income 35 53
Interest expense   (63 )   (77 )
  1,529     (1,011 )
Income before income tax expense 5,220 434
Income tax expense   2,277     212  
Net income 2,943 222
Less net income attributable to noncontrolling interest   (17 )   (16 )
Net income attributable to Lannett Company, Inc. $ 2,926   $ 206  
Earnings per common share - Lannett Company, Inc.:
Basic $ 0.10 $ 0.01
Diluted $ 0.10 $ 0.01
Weighted average number of shares outstanding:
Basic 28,278,514 28,431,733
Diluted 28,469,224 28,686,644
(In thousands, except share and per share data)

September 30, 2012 June 30, 2012

Current Assets
Cash and cash equivalents $ 26,361 $ 22,562
Investment securities 5,010 6,667
Trade accounts receivable (net of allowance of $173 and $124, respectively) 42,057 42,212
Inventories, net 27,606 27,064
Income taxes receivable - 2,120
Deferred tax assets 4,914 4,833
Other current assets   2,083     1,023  
Total Current Assets 108,031 106,481
Property, plant and equipment, net 36,811 37,068
Intangible assets, net 3,958 4,429
Deferred tax assets 8,853 9,069
Other assets   1,167     1,171  
TOTAL ASSETS $ 158,820   $ 158,218  

Current Liabilities
Accounts payable $ 12,640 $ 17,989
Accrued expenses 1,899 1,518
Accrued payroll and payroll related 2,338 3,198
Income taxes payable 1,679 -
Current portion of long-term debt 651 648
Rebates, chargebacks and returns payable   18,313     17,039  
Total Current Liabilities 37,520 40,392
Long-term debt, less current portion   6,385     6,513  
TOTAL LIABILITIES   43,905     46,905  
Commitment and Contingencies

Common stock - authorized 50,000,000 shares, par value $0.001; issued, 28,707,574
and 28,594,437 shares, respectively; outstanding, 28,297,233 and 28,252,192 shares, respectively 29 29
Additional paid in capital 100,467 99,515
Retained earnings 16,162 13,236
Accumulated other comprehensive (loss) (22 ) (63 )
Treasury stock at cost - 410,341 and 342,245 shares, respectively   (1,928 )   (1,594 )
Total Shareholders' Equity Attributable to Lannett Company, Inc. 114,708 111,123
Noncontrolling interest   207     190  
TOTAL SHAREHOLDERS' EQUITY   114,915     111,313  

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,057.40 +6.65 0.04%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.2610 +19.4730 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs